<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Dialogues Clin Neurosci</journal-id>
<journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id>
<journal-title-group>
<journal-title>Dialogues in Clinical Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1294-8322</issn>
<issn pub-type="epub">1958-5969</issn>
<publisher>
<publisher-name>Les Laboratoires Servier</publisher-name>
<publisher-loc>France</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32699506</article-id>
<article-id pub-id-type="pmc">7365295</article-id>
<article-id pub-id-type="doi">10.31887/DCNS.2020.22.1/macrocq</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurodevelopmental disorders—the history and future of a diagnostic
concept </article-title>
<trans-title-group xml:lang="es">
<trans-title>Trastornos del neurodesarrollo: historia y futuro de este concepto diagnóstico</trans-title>
</trans-title-group>
<trans-title-group xml:lang="fr">
<trans-title>Histoire et avenir des troubles neurodéveloppementaux en tant que concept diagnostique</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Morris-Rosendahl</surname>
<given-names>Deborah J.</given-names>
</name>
<degrees>PhD</degrees>
<aff>Clinical Genetics and Genomics, Royal Brompton and
Harefield NHS Foundation Trust, London, UK; NHLI, Imperial College London, UK</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Crocq</surname>
<given-names>Marc-Antoine</given-names>
</name>
<degrees>MD</degrees>
<aff>Centre Hospitalier, Rouffach, France; CAMUHA, Université de Haute-Alsace, Mulhouse,
France</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="COR1">Marc-Antoine Crocq, Maison des Adolescents, 8-10 rue des Pins, 68200
Mulhouse, France<label>*</label>
E-mail: <email>macrocq@aol.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2020</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>3</month>
<year>2020</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>72</lpage>
<permissions>
<copyright-statement>© 2019, AICHServier Group﻿Copyright © 2019 AICH Servier Group. All rights reserved</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which
permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>This article describes the history of the diagnostic class of neurodevelopmental
disorders (NDDs) up to DSM-5. We further analyze how the development of
genetics will transform the classification and diagnosis of NDDs. In
DSM-5, NDDs include intellectual disability (ID), autism spectrum
disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD). Physicians in
German-, French- and English-speaking countries (eg, Weikard, Georget, Esquirol, Down,
Asperger, and Kanner) contributed to the phenomenological definitions of these disorders
throughout the 18th and 20th centuries. These diagnostic categories show considerable
comorbidity and phenotypic overlap. NDDs are one of the chapters of psychiatric nosology
most likely to benefit from the approach advocated by the National Institute of Mental
Health’s Research Domain Criteria project. Genetic research supports the hypothesis that
ID, ASD, ADHD, schizophrenia, and bipolar disorder lie on a neurodevelopmental
continuum. The identification of recurrently observed copy number variants and
disruptive gene variants in ASD (eg, CDH8, 16p11.2, SCN2A) led to the
adoption of the genotype-first approach to characterize individuals at the etiological
level. </p>
</abstract>
<trans-abstract xml:lang="es">
<p>Este artículo describe la historia de la clase diagnóstica de los trastornos del neurodesarrollo (TND) hasta el DSM-5. Además se analiza cómo el desarrollo de la genética transformará la clasificación y el diagnóstico de los TND. En el DSM-5, los TND incluyen la discapacidad intelectual (DI), los trastornos del espectro autista (TEA) y el trastorno por déficit de atención / hiperactividad (TDAH). Los médicos en países de habla alemana, francesa e inglesa (por ejemplo, Weikard, Georget, Esquirol, Down, Asperger y Kanner) contribuyeron a las definiciones fenomenológicas de estos trastornos a lo largo de los siglos XVIII y XX. Estas categorías diagnósticas muestran una importante comorbilidad y superposición fenotípica. Los TND constituyen uno de los capítulos de la nosología psiquiátrica que tienen más probabilidades de beneficiarse con el enfoque recomendado por el proyecto Research Domain Criteria (Criterios de Dominio de Investigación) del Instituto Nacional de Salud Mental. La investigación genética respalda la hipótesis de que la DI, el TEA, el TDAH, la esquizofrenia y el trastorno bipolar se encuentran en un continuo del neurodesarrollo. La identificación y observación repetida de variaciones en el número de copias y variaciones de genes disruptivos en el TEA (p. Ej., CDH8, 16p11.2, SCN2A) condujeron a la adopción de un enfoque primariamente genético para la caracterización etiológica de los sujetos.</p>
</trans-abstract>
<trans-abstract xml:lang="fr">
<p>Dans cet article qui décrit l’histoire de la classe diagnostique des troubles neurodéveloppementaux (TND) jusqu’au DSM-5, nous analyserons comment les progrès de la génétique vont transformer leur classification et leur diagnostic. Dans le DSM-5, les TND comprennent les handicaps intellectuels (HI), les troubles du spectre de l’autisme (TSA) et le déficit de l’attention/hyperactivité (TDAHA). Ce sont des médecins issus de pays germanophones, francophones et anglophones (comme Weikard, Georget, Esquirol, Down, Asperger et Kanner) qui ont participé à la définition phénoménologique de ces troubles, du XVIIIe au XXe siècle. On observe dans ces catégories diagnostiques une comorbidité et un chevauchement des phénotypes très importants. En termes de nosologie psychiatrique, les TND seraient les plus susceptibles de bénéficier de l’approche défendue par le NIMH (National Institute of Mental Health) : le projet Research Domain Criteria (Critères des domaines de recherche). Selon la recherche génétique, le HI, les TSA, le TDAHA, la schizophrénie et les troubles bipolaires appartiendraient à un continuum neurodéveloppemental. L’idée d’une caractérisation étiologique des individus en passant d’abord par la génétique est venue de l’observation répétée au sein des TSA de variations du nombre de copies et de variations génétiques perturbatrices (par exemple CDH8, 16p11.2, SCN2A).</p>
</trans-abstract>
<kwd-group>
<kwd>
<italic>autism</italic>
</kwd>
<kwd>
<italic>intellectual disability</italic>
</kwd>
<kwd>
<italic>ADHD</italic>
</kwd>
<kwd>
<italic>neurodevelopmental disorder</italic>
</kwd>
<kwd>
<italic>RDoC</italic>
</kwd>
<kwd>
<italic>copy number variant</italic>
</kwd>
<kwd>
<italic>(CNV)</italic>
</kwd>
<kwd>
<italic> genome-wide association study (GWAS)</italic>
</kwd>
<kwd>
<italic>genetics</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>The origin of the concept of neurodevelopmental disorder </title>
<p>
“Developmental disorders” were included for the first time in
<italic>DSM-III</italic>
,
<sup><xref ref-type="bibr" rid="ref1">1</xref></sup>
for the category that comprised autistic disorder. “Neurodevelopmental disorders”
(NDDs) were introduced as an overarching disorder category in
<italic>DSM‑5</italic>
.
<sup><xref ref-type="bibr" rid="ref2">2</xref></sup>
This new section replaced a previous chapter that was termed “Disorders usually
first diagnosed in infancy, childhood, or adolescence.” In
<italic>ICD‑11</italic>
, the latest revision of the International Classification of Diseases published by
the WHO, NDDs gained even more prominence by becoming an integral part of the title
of the chapter on psychiatry: “Mental, behavioral or neurodevelopmental disorders.”
<italic>Figure 1</italic>
outlines the main categories comprising neurodevelopmental disorders in
<italic>DSM-5</italic>
, their historical background, and the hypothesis of the genetic spectrum of
neurodevelopmental disorders that will be discussed later in this article. 
</p>
<p>
In
<italic>DSM‑5</italic>
, NDDs are defined as a group of conditions with onset in the developmental period,
inducing deficits that produce impairments of functioning. NDDs comprise
intellectual disability (ID); Communication Disorders; Autism Spectrum Disorder
(ASD); Attention-Deficit/Hyperactivity Disorder (ADHD); Neurodevelopmental Motor
Disorders, including Tic Disorders; and Specific Learning Disorders. The
classification of NDDs in
<italic>ICD‑11</italic>
does not diverge significantly from that in
<italic>DSM‑5</italic>
. Importantly, all NDDs in
<italic>DSM‑5</italic>
may include the specifier “associated with a known medical or genetic condition or
environmental factor.” This specifier offers the clinician the possibility to
document etiological factors, such as fragile X syndrome, and is a harbinger of the
fact that this disorder category will probably be transformed in the coming decades
by new data emerging from genetics research. 
</p>
<fig id="d38e170" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<title>Main categories comprising neurodevelopmental disorders in <italic>DSM-5</italic>, their historical background, and  the hypothesis of the genetic spectrum of
neurodevelopmental disorders.</title>
</caption>
<graphic xlink:href="DCNS_22.1_Crocq_figure1"></graphic>
</fig>
<p>
The validity of NDDs as a construct is supported by the high rates of comorbidity
between various disorders within this diagnostic grouping. For instance, various
studies showed that 22% to 83% of children with ASD have symptoms that satisfy the
<italic>DSM-IV</italic>
criteria for ADHD, and vice versa, 30% to 65% of children with ADHD have clinically
significant symptoms of ASD.
<sup><xref ref-type="bibr" rid="ref3">3</xref></sup>
Also, although not part of the criteria of ASD, accompanying intellectual or
language impairments are frequent in ASD and their presence must be specified. NDDs
share the characteristic of being diagnosed more often in males than females;
<italic>DSM-5</italic>
mentions male-to-female ratios of 4:1 for the diagnosis of ASD, 2:1 for the
diagnosis of ADHD in children, and 1.6:1 and 1.2:1 for mild and severe ID,
respectively. The idea of gathering these various disorders into one single
diagnostic group came with
<italic>DSM-5</italic>
. As late as in the 10
<sup>th</sup>
edition of Kaplan &amp; Sadock’s comprehensive textbook of psychiatry (2017),
Attention-Deficit Disorders (ADD), ASD, and ID were distinct disorders whose only
commonality was being part of child psychiatry. According to German E. Berrios,
<sup><xref ref-type="bibr" rid="ref4">4</xref></sup>
the historian of psychiatry, the concept of developmental disorder in psychiatry
appeared for the first time in 1820 in a textbook by Étienne Jean Georget
(1795-1828), a student of Philippe Pinel (1745-1826) and Jean-Étienne Esquirol
(1772-1840), the pioneers of a modern psychiatric nosology based on mental symptoms
instead of humoral concepts. Pinel translated William Cullen’s nosology into French
in 1785, and published his own classification of mental illnesses in 1801; in his
nosography, idiocy was a psychiatric disorder, along with mania, melancholia, and
dementia. Correcting Pinel’s nosography to further delineate the field of mental
illness, Georget
<sup><xref ref-type="bibr" rid="ref5">5</xref></sup>
wrote (p 102) that Idiocy is “
<italic>a lack of development of intellectual faculties,</italic>
” (emphasis added) and he added in a footnote that “a
<italic>developmental defect</italic>
is not, strictly speaking, a
<italic>disease</italic>
,” and that “idiots should be classified among
<italic>monsters</italic>
.” At a distance of two centuries, the word “monster” should not be read
anachronistically as an insult, but as a reference to a genetic abnormality in the
human body. Within the larger group of idiots, Georget included a subtype of
“imbeciles,” with higher cognitive abilities. Georget died at the early age of 33,
and Berrios suggests that Esquirol later adopted Georget’s developmental view,
without quoting him. Esquirol
<sup><xref ref-type="bibr" rid="ref6">6</xref></sup>
criticized Pinel for having differentiated dementia and idiocy on the sole basis of
the degree of impairment of intelligence—Pinel considered idiocy as the most severe
degree of dementia—and for admitting the existence of both acquired and innate
idiocy. Instead, Esquirol stated that idiocy was not an illness, but a condition in
which intellectual faculties could not achieve sufficient
<italic>development</italic>
. This statement by Esquirol has often been quoted in various textbooks over the
following two centuries. Esquirol stated that there were innumerable degrees of
severity and, like Georget, he distinguished two main categories: idiocy per se, a
severe intellectual impairment, and imbecility, a mild or moderate impairment. In
Georget’s suggestive words, imbeciles “have memory, can judge simple acts of life …
are clean, know how to appreciate the difference between the sexes,” whereas “the
idiots urinate and defecate wherever they are and are often very prone to
masturbation” (p 104). 
</p>
</sec>
<sec>
<title>Early descriptions of ADHD, intellectual disabilities, and
ASD </title>
<p>
The symptoms of various NDDs were described long before the diagnostic concepts were
delineated from each other in the mid-20
<sup>th</sup>
century. 
</p>
<sec>
<title>ADHD </title>
<p>
The first known description of attention deficit was published in 1775 by the German
physician Melchior Adam Weikard, under the name Mangel der Aufmerksamkeit/Attentio
volubilis, in a book entitled
<italic>Der philosophische Arzt</italic>
.
<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>
This work was the subject of several editions. Weikard (1742-1803) began his medical
career in 1764 in Bavaria, near his birthplace, as a doctor at the Bad Brückenau
spa. In 1784 he was appointed doctor at the court of Empress Catherine II of Russia.
He was known as a scholar and was a prolific author. In an edition of his book
published in 1799,
<sup><xref ref-type="bibr" rid="ref8">8</xref></sup>
Weikard devoted six pages to the description of attention deficit. He describes how
sensory stimuli capture the patient’s attention and divert him from his thoughts:
“... it is easier to perceive impressions through the sense organs than to form or
retain ideas, to recover past memories or to do other reflective operations. Each
sense can disturb us in our thoughts or thinking, distract us from our object and
draw our attention to something else. Of all the senses, this occurs most often with
hearing and sight. The result is distraction, lack of attention, inattention.” The
Latin term “volubilis” comes from the verb “volvere” (to turn). The literal meaning
of Volubilis is “easily rotating,” and by extension “fickle” or “changing.” This
image of a permanent rotation of ideas is sometimes used by some patients who relate
the subjective feeling that their attention does not hold in place but twirls. 
</p>
</sec>
<sec>
<title>Separating ASD from mental retardation </title>
<p>
The terms “idiocy” and “imbecility” are attested to by the Oxford English Dictionary
as early as the 16th century. Also, behaviors consistent with autism were described
long before that diagnostic category was named and defined by Leo Kanner
<sup><xref ref-type="bibr" rid="ref9">9</xref></sup>
in 1943 and Hans Asperger
<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>
in 1944. Russian specialists
<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>
suppose that many of the “holy fools,” or Orthodox church ascetics (yuródivïe) who
roamed ancient Russia displayed autistic behaviors, being notoriously nonverbal,
impervious to social conventions, and indifferent to cold weather or pain. Famous
cases showed that some “idiots” had specific problems in social
communication—consistent with autism—rather than a mere global mental deficiency.
One such case is Victor, the Wild Boy of Aveyron (c 1788-1828), a feral child who
was discovered when he was about 12. Victor was taken to Paris, and his case was
taken up by a young physician, Jean Itard, who tried to instruct him and repeatedly
assessed his sensory, intellectual, and affective progress over 5 years. Edouard
Seguin
<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>
(1812-1880), a pioneer of the education of children with intellectual disability,
first in France and afterward in the United States, recounted the various diagnostic
hypotheses discussed at the time. According to Seguin, Pinel had declared Victor
“idiotic” and therefore uneducable; Itard, on the other hand, asserted that the
child was wild and entirely untaught. Itard’s observations over the following years
suggest that both diagnoses might have been erroneous and that Victor might have
been a child with autism, abandoned by his parents. As Itard reports, Victor
demonstrated aberrant requesting strategies like the use of hand-over-hand (eg,
Victor once seized Itard’s hand and directed it to a locked door to ask him to open
it), he was using others as tools to satisfy his needs, a hallmark of the clinical
picture was his difficulty initiating and maintaining social relationships, and even
though he learned letters and some spelling, he could not use this knowledge in a
regular interaction with others. 
</p>
<p>
Dr J. Langdon Down (1828-1896) is best known for having described Down’s syndrome
(trisomy 21). In a series of lectures delivered before the Medical Society of London
in 1887,
<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>
he also described 10 cases of “idiots savants,” patients with exceptional abilities
in an extremely narrow field, such as calendar calculating. While these cases were
not all autistic, most of them would now satisfy Criterion B for ASD in DSM‑5 (ie,
restricted and repetitive patterns of behavior, interest, or activities). In papers
published after these lectures,
<sup><xref ref-type="bibr" rid="ref14">14</xref></sup>
Down based himself on three decades of clinical experience to propose a
classification of mental retardation into (i) “congenital;” (ii) “accidental;” and
(iii) a third kind which he termed “developmental.” The latter type occurred in
children who did not have the usual “physical aspects” of retardation. Some of these
children had developed normally “until the period of second dentition,” and then
suddenly regressed, lost their “wonted brightness” and speech, lived “in a world of
their own,” spoke “in the third person,” had “rhythmical and automatic movements”
and “lessened responsiveness to all endearments of friends.” Treffert
<sup><xref ref-type="bibr" rid="ref15">15</xref></sup>
comments on Down’s interesting choice of the term “developmental retardation” for
this category that probably corresponds to cases of both early-onset and late-onset
regressive autism. 
</p>
<p>
We have so far described the history of the diagnostic categories, based on
phenomenological definitions, that came to comprise the NDDs in
<italic>DSM-5</italic>
. We will now discuss how these psychopathological concepts can fare in the era of
neurosciences. 
</p>
</sec>
</sec>
<sec>
<title>How far along are we to a new molecular  or genetic
classification? </title>
<p>
With the increasing appreciation of the considerable phenotypic overlap between NDDs,
there has been a general trend to move away from the classification of disorders as
discrete entities, to placing them within a spectrum. This is illustrated by the
single diagnostic label for ASD in
<italic>DSM-5</italic>
, which subsumes all previously designated subtypes. The classification is still
mostly based on behavioral phenotypes and the Research Domain Criteria (RDoC)
project by the National Institute of Mental Health has been calling for analysis at
the genetic levels.
<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup>
With rapid advances in molecular biology, genetics, and genomics, neuropsychiatric
disorders are increasingly grouped by their biology and in particular, the genes and
variants that have been found to cause them. The clinical heterogeneity in NDDs is,
however, reflected in extreme genetic heterogeneity, with a genetic diagnosis not
possible for most cases. Unlike Mendelian disorders, such complex disorders are
defined by a phenotype that is not caused by one or two pathogenic variants in a
single gene, but rather by many genetic events with significant contribution from
environmental factors. Disorders which have a simple genetic cause comprise a small
fraction of the spectrum of NDDs, so the challenge is to develop even better
approaches to link phenotype and genotype for NDDs. 
</p>
<p>
Genetic studies of complex diseases traditionally followed a pathway from phenotype
to genotype to gene, a so-called “forward genetics” approach. Most disease genes
have, however, been identified by an approach known as “reverse genetics,” ie, the
identification of a gene via its chromosomal location, without prior knowledge of
its protein product or the molecular pathway in which it functions. The development
of techniques to generate large amounts of genetic data by genome-wide genotyping
has allowed genetic research to increasingly focus on the use of unbiased
genome-wide approaches to gene identification. This led to the concept of “reverse
phenotyping.”
<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>
In this approach, genetic markers are used to drive, or form the basis of new
phenotypic definitions, so that phenotypes are refined based on genetic marker data.
The goal is to define phenotypic groupings that are distinguished by higher rates of
allele-sharing (linkage data) or more deviant allele frequencies (association data)
than are seen in the traditional diagnostic categories. This “genotype-first”
approach was elegantly elaborated by Stessman et al
<sup><xref ref-type="bibr" rid="ref19">19</xref></sup>
as a way of defining the subtypes of a complex disease. They defined a “genetic
subtype” as a gene in which recurrent mutations show an excess of burden in patients
versus controls. A “molecular subtype,” on the other hand, constitutes a group of
genetic subtypes that are linked together in a common pathway (eg coexpression,
protein interaction network, etc).
<sup><xref ref-type="bibr" rid="ref20">20</xref></sup>
 
</p>
</sec>
<sec>
<title>The hypothesis of a genetic neurodevelopmental continuum </title>
<p>
Over the past decade, evidence has been accumulating that childhood
neurodevelopmental disorders such as ID, ASD, and ADHD share specific genetic risk
alleles with each other, as well as with psychiatric disorders, particularly
schizophrenia.
<sup><xref ref-type="bibr" rid="ref21">21</xref></sup>
Copy number variants (CNVs) associated with ID were significantly enriched in
patients with schizophrenia, supporting the view that many additional ID-related
variants also confer risk to schizophrenia, but at reduced penetrance.
<sup><xref ref-type="bibr" rid="ref22">22</xref></sup>
This has led authors to propose the model of a neurodevelopmental continuum, in
which neurodevelopmental disorders, including schizophrenia, are seen as
representing the diverse range of outcomes that follow from disrupted or deviant
brain development.
<sup><xref ref-type="bibr" rid="ref23">23</xref></sup>
Thus, childhood neurodevelopmental disorders (ID, ASD, ADHD) and adult psychiatric
disorders (including both bipolar disorder [BPD] and schizophrenia) could better be
conceptualized as lying on an etiological and neurodevelopmental continuum, rather
than being defined as discrete entities. The model is based on emerging evidence for
shared genetic and environmental risk factors and predicts that there are likely
overlapping pathogenic mechanisms. The authors have taken this model one step
further and have proposed the neurodevelopmental gradient hypothesis, in which
disorders are graded according to the severity of neurodevelopmental impairment.
Contributing features to this grading are age of onset relative to the typical age
of onset for each of the disorders, the severity of associated cognitive impairment
and the persistence of functional impairment. Although this model may appear to be a
gross oversimplification of the diagnostic conundrum, it posits that the degree of
neurodevelopmental impairment is currently the most recognizable of these features
and makes clear predictions about the relative importance of the most damaging
classes of rare genetic variants. In support of this hypothesis, Girirajan et al
<sup><xref ref-type="bibr" rid="ref24">24</xref></sup>
have shown that the burden of DNA CNVs is positively correlated with the severity of
childhood neurodevelopmental disorders, being greater in ID than in ASD, and greater
in ASD with ID than in those children without ID. Kirov et al
<sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
have shown that the burden of large, rare CNVs implicated in neurodevelopmental
disorders is greater in cases with developmental delay, autism, or congenital
malformations, than in schizophrenia. The enrichment of rare mutations appears to be
correlated with the degree of cognitive impairment both across and within diagnostic
groups, but pathogenic CNVs and rare coding variants are found in ASD and
schizophrenia, without gross cognitive impairment. Pathogenic CNVs are also found in
individuals with subtle impairments of cognition but who do not have psychiatric
diagnosis. 
</p>
<p>
Neurodevelopmental disorders are associated with reduced fecundity.
<sup><xref ref-type="bibr" rid="ref26">26</xref></sup>
One can postulate then, that genetic variants that confer a high risk for those
disorders should be rare in the population due to negative selection. The frequency
of such variants in the population should be a function of that selection pressure
and the rate of replacement due to new, or de novo mutation. The increased rate of
de novo variants in most neurodevelopmental disorders, supports this postulation.
Individuals with severe, undiagnosed developmental disorders (DDs) are enriched for
damaging de novo mutations (DNMs) in developmentally important genes (the
Deciphering Developmental Disorders Study [DDDS], 2017).
<sup><xref ref-type="bibr" rid="ref27">27</xref></sup>
In a large whole-exome sequencing study of 4293 families with individuals with
developmental disorders and meta-analysis of data with another 3287 individuals with
similar disorders, the DDDS identified 94 genes enriched for damaging de novo
mutations (DNMs). The authors estimated that 42% of the cohort carried pathogenic
DNMs in coding sequences, and approximately half disrupt gene function, with the
remainder resulting in altered function. They concluded that de novo mutations
account for approximately half of the genetic architecture of severe developmental
disorders and more than 40% in intellectual disability. A large study of autism
found the de novo mutation rate to be 5.2% in patients compared with 1.6% in
unaffected siblings.
<sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
When the relative enrichment for de novo variants is compared across disorders, the
rates are once again in decreasing frequency when placed against a gradient, from ID
to ASD to schizophrenia, in line with predictions from the gradient hypothesis. 
</p>
<p>
One can also explore whether the same genes or sets of functionally related genes
tend to be implicated across neurodevelopmental disorders, and this appears to be
the case. The same set of genes affected by loss of function de novo mutations are
enriched in data from patients with ID, ASD, and schizophrenia.
<sup><xref ref-type="bibr" rid="ref29">29</xref></sup>
Functionally, rare de novo and rare damaging coding variants tend to cluster broadly
in similar biological processes, such as synaptic plasticity, chromatin
modification, and targets of fragile X mental retardation protein, indicating that
the same pathogenic mechanism may be affected across disorders.
<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup>
 
</p>
</sec>
<sec>
<title>How can these findings be used in diagnosis  and classification? ASD as a model
for  the genotype-first approach </title>
<p>
The ASD population is etiologically and phenotypically heterogeneous. The genetic
etiology of ASD is no less varied. Heritability of autism is high, with estimates
ranging from 50% to 90%
<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup>
and rates of recurrence among non-twin siblings approaching 20%.
<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>
ASD not only has shared phenotypic overlap with many syndromic forms, such as Down
syndrome, Prader-Willi/Angelman syndrome, and Fragile X-linked ID (about 4% to 5% of
ASD),
<sup><xref ref-type="bibr" rid="ref35">35</xref></sup>
but as described above, is also one of the disorders for which rare variants have
been demonstrated to have a strong effect. Over 100 genes and genomic regions have
been associated with ASD, and over 800 genes have been suggested to play a role in
ASD. 
</p>
<p>
Additive polygenic factors explain many ASD cases, especially those at the milder
ends of the spectrum, and genome-wide association studies (GWAS) have provided
support for the contribution of common DNA variants to the broader ASD
phenotype.
<sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
Sebat et al
<sup><xref ref-type="bibr" rid="ref37">37</xref></sup>
used a trio approach of an affected proband and their unaffected parents, to perform
high-resolution DNA arrays to detect de novo CNVs in affected children. Their
studies highlighted the power of identifying de novo events as likely causal
variants across a broad range of genetic loci. De novo CNVs were up to ten times
more prevalent in patients affected with ASD than in unaffected individuals.
<sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
De novo pathogenic variants and CNVs are now estimated to account for approximately
30% of simplex cases of ASD. 
</p>
<p>
The identification of recurrently observed CNVs and disruptive gene variants in ASD
led to the adoption of the genotype-first approach to characterize individuals at
the etiological level. The genotype-first approach has led to the identification of
ASD-specific genetic subtypes, variant-specific phenotypic spectra, and promising
pharmacological treatment targets and psychosocial benefits to affected
families.
<sup><xref ref-type="bibr" rid="ref39">39</xref></sup>
One of the first subtypes to be described was that for heterogeneous, disruptive
variants in
<italic>CHD8</italic>
.
<italic>CDH8</italic>
is involved in chromatin remodeling and its targets include many other genes that
have also been associated with ASD.
<sup><xref ref-type="bibr" rid="ref40">40</xref></sup>
The
<italic>CDH8</italic>
genetic subtype includes physical characteristics such as macrocephaly, dysmorphic
facial features, and gastrointestinal complaints and is more specific to ASD (≥87%)
than to ID (~60%). 
</p>
<p>
In contrast to the fairly narrow phenotype defined in carriers of pathogenic
<italic>CDH8</italic>
variants, Steinman et al
<sup><xref ref-type="bibr" rid="ref41">41</xref></sup>
were able to delineate the differences between carriers of the 16p11.2 CNV. The
16p11.2 deletion neurologic phenotype was characterized by highly prevalent speech
articulation abnormalities, limb and trunk hypotonia with hyporeflexia,
 abnormalities of agility, sacral dimples, seizures/epilepsy, large head
size/macrocephaly, and Chiari I/cerebellar tonsillar ectopia. Duplication carriers
demonstrated more prominent hyperreflexia; less, though still prevalent,
hyporeflexia; highly prevalent action tremor; small head size/microcephaly; and
cerebral white matter/corpus callosum abnormalities and ventricular enlargement. The
neurologic phenotypes of these reciprocal 16p11.2 CNVs included both shared and
distinct features. The 16p11.2 phenotype eludes simple classification, spanning more
than 20 different disorders in older
<italic>DSM</italic>
classifications.
<sup><xref ref-type="bibr" rid="ref42">42</xref></sup>
Although the majority of patients would not qualify as autistic by this definition,
some aspects of the 16p11.2 deletion phenotype are remarkably consistent and
reminiscent of a “type of autism” not yet recognized by the
<italic>DSM</italic>
. These conclusions highlight the power of the genotype-first-based approach. 
</p>
<p>
A similar dichotomy was observed in individuals with pathogenic <italic>SCN2A</italic> variants. Disruption of the gene <italic>SCN2A</italic> has been identified as one of the main causes of a wide variety of neurodevelopmental disorders, including benign familial neonatal-infantile seizures, infantile epileptic encephalopathy and ASD/ID.<sup><xref ref-type="bibr" rid="ref43">43</xref>-<xref ref-type="bibr" rid="ref47">47</xref></sup> Gain of function variants resulting in increased Nav1.2 channel function have been associated with infant-onset seizures and encephalopathy, whereas loss-of-function variants conveying diminished channel function led to ASD and/or intellectual disability.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> The consequences of disease-associated variants on protein function can have predictive value regarding the nature and severity of the resulting phenotype. <italic>SCN2A</italic> encodes a subunit of the neuronal voltage-gated sodium channel NaV1.2, which is involved in the initiation and the propagation of action potentials. Knowledge of the physiology of sodium channels and the known phenotype-genotype correlations relating to <italic>SCN2A</italic>, make it an important target for a precision medicine approach to therapy for ASD and other neurodevelopmental disorders.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup>
</p>
</sec>
<sec>
<title>Conclusion </title>
<p>
The historic use of categorical diagnoses and classifications has failed NDDs in that
the boundaries between disorders are not clear and comorbidity is common. The
neurodevelopmental continuum underscores the need for new and flexible approaches to
diagnosis and patient stratification, and the high degree of pleiotropy suggests
that therapeutic approaches may be fruitful across diagnostic boundaries. 
</p>
<p>
The rate of disease gene identification has accelerated dramatically over the past
decade and with whole-exome and genome sequencing becoming increasingly routine
practice, the genotype-first approach will likely soon spread beyond autism and
developmental delay to include genes and CNVs associated with other psychiatric
disorders. This surge in technological development to generate large datasets has
been accompanied by increasing sophistication in the statistical methods used for
data analysis. While genetically informed targeted therapies are the ultimate goal
of precision medicine, there are substantial clinical and psychosocial benefits to
the genotype-first approach. For families, this will translate into better diagnosis
and counseling, and the formation of patient-driven support groups. Family groups
associated with specific genetic subtypes can be mobilized to support one another,
share experiences, and work closely with clinicians and researchers to enrol
participants for research projects, to provide valuable phenotypic data and to place
them in the front line for potential clinical trials. 
</p>
</sec>
</body>
<back>
<ack>
<p>The authors have no conflict of interest in relation to the content of this
article</p>
</ack>
<ref-list>
<title>REFERENCES</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="book">
<collab>American Psychiatric Association</collab>
<source/>Diagnostic and Statistical Manual of Mental Disorders

          <year>1980</year>
<publisher-loc>Washington, DC</publisher-loc>
<publisher-name>American Psychiatric Association Publishing</publisher-name>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="book">
<collab>American Psychiatric Association</collab>
<source/>Diagnostic and Statistical Manual of Mental Disorders

          <year>2013</year>
<publisher-loc>Arlington, VA</publisher-loc>
<publisher-name>American Psychiatric Association Publishing</publisher-name>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sokolova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Oerlemans</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Rommelse</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>A causal and mediation analysis of the comorbidity between attention
deficit hyperactivity disorder (ADHD) and ASD</article-title>
<source/>
<italic>J Autism Dev Disord</italic>
<year>2017</year>
<volume>47</volume>
<issue>6</issue>
<fpage>1595</fpage>
<lpage>1604</lpage>
<pub-id pub-id-type="pmid">28255761</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Berrios</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R</given-names>
</name>
</person-group>
<source/>A History of Clinical Psychiatry. The Origin and History of Psychiatric
Disorders

          <year>1995</year>
<publisher-loc>London, UK</publisher-loc>
<publisher-name>The Athlone Press</publisher-name>
<fpage>228</fpage>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Georget</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<source/>De la folie. Considérations sur cette maladie

          <year>1820</year>
<publisher-loc>Paris, France</publisher-loc>
<publisher-name>Crévot</publisher-name>
<fpage>102</fpage>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Esquirol</surname>
<given-names>E</given-names>
</name>
</person-group>
<source/>Des maladies mentales

          <year>1838</year>
<publisher-loc>Paris, France</publisher-loc>
<publisher-name>Baillière</publisher-name>
<fpage>284</fpage>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barkley</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The earliest reference to ADHD in the medical literature? Melchior Adam
Weikard’s description in 1775 of “Attention Deficit” (Mangel der Aufmerksamkeit,
Attentio Volubilis)</article-title>
<source/>
<italic>J Attention Disord</italic>
<year>2012</year>
<volume>16</volume>
<issue>8</issue>
<fpage>623</fpage>
<lpage>630</lpage>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Weikard</surname>
<given-names>MA</given-names>
</name>
</person-group>
<source/>Der philosophische Arzt

          <year>1799</year>
<fpage>36</fpage>
<lpage>41</lpage>
<comment>Available at:https://hdl.handle.net/2027/ucm.532772908x</comment>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanner</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Autistic disturbances of affective contact</article-title>
<source/>
<italic>Nervous Child</italic>
<year>1943</year>
<volume>2</volume>
<fpage>217</fpage>
<lpage>250</lpage>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asperger</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Die „Autistischen Psychopathen“ im Kindesalter</article-title>
<source/>
<italic>Archiv für Psychiatrie und Nervenkrankheiten</italic>
<year>1944</year>
<volume>117</volume>
<issue>1</issue>
<fpage>132</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mal’tinskaya</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>The history of the concept of autism</article-title>
<source/>
<italic>Koncept</italic>
<year>2017</year>
<date-in-citation>Accessed August 10, 2019</date-in-citation>
<fpage>S11</fpage>
<comment>Available at:http://e-koncept.ru/2017/470137.htm (in Russian)</comment>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Seguin</surname>
<given-names>E</given-names>
</name>
</person-group>
<source/>Idiocy and Its Treatment by the Physiological Method

          <year>1866</year>
<publisher-loc>New York, NY</publisher-loc>
<publisher-name>William Wood</publisher-name>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treffert</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>The savant syndrome: an extraordinary condition. A synopsis: past,
present, future</article-title>
<source/>
<italic>Phil Trans R Soc B</italic>
<year>2009</year>
<volume>364</volume>
<fpage>1351</fpage>
<lpage>1357</lpage>
<pub-id pub-id-type="pmid">19528017</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Down</surname>
<given-names>JL</given-names>
</name>
</person-group>
<source/>On some of the mental affections of childhood and youth, being the
Lettsomian Lectures delivered before the Medical Society of London in
1887

          <year>1887</year>
<publisher-loc>London, UK</publisher-loc>
<publisher-name>J &amp; A Churchill</publisher-name>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treffert</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Dr Down and “developmental disorders.”</article-title>
<source/>
<italic>J Autism Dev Disord</italic>
<year>2006</year>
<volume>36</volume>
<fpage>965</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-006-0183-1</pub-id>
<pub-id pub-id-type="pmid">16960762</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Commentary. Research Domain Criteria (RDoC): Toward a new classification
framework for research on mental disorders</article-title>
<source/>
<italic>Am J Psychiatry</italic>
<year>2010</year>
<volume>167</volume>
<issue>7</issue>
<fpage>748</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="pmid">20595427</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crocq</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Can psychopathology and neuroscience coexist in psychiatric
classifications?</article-title>
<source/>
<italic>Dialogues Clin Neurosci</italic>
<year>2018</year>
<volume>20</volume>
<fpage>155</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="pmid">30581284</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulze</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>Defining the phenotype in human genetic studies: Forward genetics and
reverse phenotyping</article-title>
<source/>
<italic>Hum Hered</italic>
<year>2014</year>
<volume>58</volume>
<fpage>131</fpage>
<lpage>138</lpage>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stessman</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>A genotype-first approach to defining the subtypes of a complex
disease</article-title>
<source/>
<italic>Cell</italic>
<year>2014</year>
<volume>156</volume>
<issue>5</issue>
<fpage>872</fpage>
<lpage>877</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2014.02.002</pub-id>
<pub-id pub-id-type="pmid">24581488</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of
de novo mutations</article-title>
<source/>
<italic>Nature</italic>
<year>2012</year>
<volume>485</volume>
<fpage>246</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<pub-id pub-id-type="pmid">22495309</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O‘Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Thapar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Craddock</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Neurodevelopmental hypothesis of schizophrenia</article-title>
<source/>
<italic>Br J Psychiatry</italic>
<year>2011</year>
<volume>198</volume>
<issue>3</issue>
<fpage>173</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.110.084384</pub-id>
<pub-id pub-id-type="pmid">21357874</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>JTR</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>The contribution of rare variants to risk of schizophrenia in individuals
with and without intellectual disability</article-title>
<source/>
<italic>Nat Genet</italic>
<year>2017</year>
<volume>49</volume>
<issue>8</issue>
<fpage>1167</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="pmid">28650482</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O‘Donovan</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Schizophrenia and the neurodevelopmental continuum: evidence from
genomics</article-title>
<source/>
<italic>World Psychiatry</italic>
<year>2017</year>
<volume>16</volume>
<issue>3</issue>
<fpage>227</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20440</pub-id>
<pub-id pub-id-type="pmid">28941101</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brkanac</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Relative burden of large CNVs on a range of neurodevelopmental
phenotypes</article-title>
<source/>
<italic>PLoS Genet</italic>
<year>2011</year>
<volume>7</volume>
<fpage>e1002334</fpage>
<pub-id pub-id-type="pmid">22102821</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>JTR</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>The penetrance of copy number variations for schizophrenia and
developmental delay</article-title>
<source/>
<italic>Biol Psychiatry</italic>
<year>2014</year>
<volume>75</volume>
<fpage>378</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="pmid">23992924</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Power</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kyaga</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Uher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Fecundity of patients with schizophrenia, autism, bipolar disorder,
depression, anorexia nervosa, or substance abuse vs their unaffected
siblings</article-title>
<source/>
<italic>JAMA Psychiatry</italic>
<year>2013</year>
<volume>70</volume>
<fpage>22</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">23147713</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McRae</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Deciphering Developmental Disorders Study. Prevalence and architecture of
de novo mutations in developmental disorders</article-title>
<source/>
<italic>Nature</italic>
<year>2017</year>
<volume>542</volume>
<issue>7642</issue>
<fpage>433</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1038/nature21062</pub-id>
<pub-id pub-id-type="pmid">28135719</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Insights into autism spectrum disorder genomic architecture and biology
from 71 risk loci</article-title>
<source/>
<italic>Neuron</italic>
<year>2015</year>
<volume>87</volume>
<issue>6</issue>
<fpage>1215</fpage>
<lpage>1233</lpage>
<pub-id pub-id-type="pmid">26402605</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pocklington</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>De novo mutations in schizophrenia implicate synaptic
networks</article-title>
<source/>
<italic>Nature</italic>
<year>2014</year>
<volume>506</volume>
<fpage>179</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">24463507</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iossifov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum
disorder</article-title>
<source/>
<italic>Nature</italic>
<year>2014</year>
<volume>515</volume>
<fpage>216 221</fpage>
<pub-id pub-id-type="pmid">25363768</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugathan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Biagioli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golzio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>CHD8 regulates neurodevelopmental pathways associated with autism
spectrum disorder in neural progenitors</article-title>
<source/>
<italic>Proc Natl Acad Sci U S A</italic>
<year>2014</year>
<volume>111</volume>
<fpage>E4468</fpage>
<lpage>E4477</lpage>
<pub-id pub-id-type="pmid">25294932</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallmayer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Genetic heritability and shared environmental factors among twin pairs
with autism</article-title>
<source/>
<italic>Arch Gen Psychiatry</italic>
<year>2011</year>
<volume>68</volume>
<issue>11</issue>
<fpage>1095</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="pmid">21727249</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Happé</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rijsdijk</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Heritability of autism spectrum disorders: a meta-analysis of twin
studies</article-title>
<source/>
<italic>J Child Psychol Psychiatry</italic>
<year>2016</year>
<volume>57</volume>
<issue>5</issue>
<fpage>585</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="pmid">26709141</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozonoff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Recurrence risk for autism spectrum disorders: a Baby Siblings Research
Consortium study</article-title>
<source/>
<italic>Pediatrics</italic>
<year>2011</year>
<volume>128</volume>
<issue>3</issue>
<fpage>e488</fpage>
<lpage>e495</lpage>
<pub-id pub-id-type="pmid">21844053</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tammimies</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Molecular diagnostic yield of chromosomal microarray analysis and
whole-exome sequencing in children with autism spectrum disorder</article-title>
<source/>
<italic>JAMA</italic>
<year>2015</year>
<volume>314</volume>
<issue>9</issue>
<fpage>895</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="pmid">26325558</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Arking</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Chakravarti</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Gene Discovery Project of Johns Hopkins &amp; the Autism Consortium. A
genome-wide linkage and association scan reveals novel loci for
autism</article-title>
<source/>
<italic>Nature</italic>
<year>2009</year>
<volume>461</volume>
<issue>7265</issue>
<fpage>802</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="pmid">19812673</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sebat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lakshmi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>D</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Strong association of de novo copy number mutations with
autism</article-title>
<source/>
<italic>Science</italic>
<year>2007</year>
<volume>316</volume>
<issue>5823</issue>
<fpage>445</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="pmid">17363630</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ercan-Sencicek</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Hus</surname>
<given-names>V</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Multiple recurrent de novo CNVs, including duplications of the 7q11.23
Williams syndrome region, are strongly associated with autism</article-title>
<source/>
<italic>Neuron</italic>
<year>2011</year>
<volume>70</volume>
<issue>5</issue>
<fpage>863</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="pmid">21658581</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnett</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The state of research on the genetics of autism spectrum disorder:
methodological, clinical and conceptual progress</article-title>
<source/>
<italic>Curr Opin Psychol</italic>
<year>2019</year>
<volume>27</volume>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">30059871</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muhle</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>The autism-associated chromatin modifier CHD8 regulates other autism risk
genes during human neurodevelopment</article-title>
<source/>
<italic>Nat Commun</italic>
<year>2015</year>
<volume>6</volume>
<fpage>6404</fpage>
<lpage>6434</lpage>
<pub-id pub-id-type="pmid">25752243</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinman</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Spence</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ramocki</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>16p.2 deletion and duplication: characterizing neurologic phenotypes in a
large clinically ascertained cohort</article-title>
<source/>
<italic>Am J Med Genet A</italic>
<year>2016</year>
<volume>170</volume>
<fpage>2943</fpage>
<lpage>2955</lpage>
<pub-id pub-id-type="pmid">27410714</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duyzend</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Genotype-first analysis of the 16p.2 deletion defines a new type of
“autism”</article-title>
<source/>
<italic>Biol Psychiatry</italic>
<year>2015</year>
<volume>77</volume>
<fpage>769</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="pmid">25843334</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heron</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Crossland</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Andermann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Sodium-channel defects in benign familial neonatal-infantile seizures</article-title>
<source/>
<italic>Lancet</italic>
<year>2002</year>
<volume>360</volume>
<fpage>851</fpage>
<lpage>852</lpage>
<pub-id pub-id-type="pmid">12243921</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy</article-title>
<source/>
<italic>Ann. Neurol</italic>
<year>2004</year>
<volume>55</volume>
<fpage>550</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="pmid">15048894</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogiwara</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sawaishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies</article-title>
<source/>
<italic>Neurology</italic>
<year>2009</year>
<volume>73</volume>
<fpage>1046</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="pmid">19786696</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Anttonen</surname>
<given-names>A-K</given-names>
</name>
<name>
<surname>Liukkonen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain</article-title>
<source/>
<italic>Neurology</italic>
<year>2010</year>
<volume>75</volume>
<fpage>1454</fpage>
<lpage>1458</lpage>
<pub-id pub-id-type="pmid">20956790</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Murtha</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>De novo mutations revealed by whole-exome sequencing are strongly associated with autism</article-title>
<source/>
<italic>Nature</italic>
<year>2012</year>
<volume>485</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">22495306</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Shalom</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Keeshen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Berrios</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>An</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Opposing effects on Na(V)1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures</article-title>
<source/>
<italic>Biol Psychiatry</italic>
<year>2017</year>
<volume>82</volume>
<fpage>224</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="pmid">28256214</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Cottrell</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>et al</surname>
<given-names></given-names>
</name>
</person-group>
<article-title>Progress in understanding and treating SCN2A-mediated disorders</article-title>
<source/>
<italic>Trends Neurosci</italic>
<year>2018</year>
<volume>41</volume>
<issue>7</issue>
<fpage>442</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="pmid">29691040</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>